Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 5/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | GRIA4 | P48058 | 5/20 | 0.47 |
| ▸ | KDM1A | O60341 | 9/20 | 0.45 |
| ▸ | MAOA | P21397 | 8/20 | 0.45 |
| ▸ | MAOB | P27338 | 8/20 | 0.45 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 0.45 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.45 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3193338 | 1.00 | GRIA2 (0.47) | GRIA2KCNH2NPC1RAB9AGRIA4 | |
| SCHEMBL3193322 | 1.00 | GRIA2 (0.47) | GRIA2KCNH2NPC1RAB9AGRIA4 | |
| SCHEMBL3210595 | 0.88 | GRIA2 (0.53) | GRIA2KCNH2GRIA4KDM1AMAOA | |
| SCHEMBL3210609 | 0.88 | GRIA2 (0.53) | GRIA2KCNH2GRIA4KDM1AMAOA | |
| SCHEMBL3210605 | 0.88 | GRIA2 (0.53) | GRIA2KCNH2GRIA4KDM1AMAOA | |
| SCHEMBL3184252 | 0.88 | GRIA2 (0.47) | GRIA2KCNH2GRIA4 | |
| SCHEMBL3184258 | 0.88 | GRIA2 (0.47) | GRIA2KCNH2GRIA4 | |
| SCHEMBL3184237 | 0.88 | GRIA2 (0.47) | GRIA2KCNH2GRIA4 | |
| SCHEMBL3264853 | 0.86 | GRIA2 (0.57) | GRIA2KCNH2GRIA4 | |
| SCHEMBL3195830 | 0.86 | GRIA2 (0.57) | GRIA2KCNH2GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035865-A1 | Sulfonamides and Pharmaceutical Compositions Thereof | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035865-A1 | Sulfonamides and Pharmaceutical Compositions Thereof | STS, SULT2A1, SULT1A1 | GRIA2 3748/4885KCNH2 1167/4885NPC1 2217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.